Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD
- Written by PR Newswire
SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, proudly announced the Phase I data of LP-003 (new...
Read more: Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD














